Pfizer: positive results in a study on HIV-1

(CercleFinance.com) - ViiV Healthcare, the HIV unit of GSK, and Pfizer reported positive results at 48 weeks in their 'Tango' phase III study on the two-drug regimen of dolutegravir plus lamivudine in adults living with HIV-1.



This study achieved its principal objective which was to demonstrate the capacity to maintain similar rates of viral suppression in patients as with a three-drug regimen followed previously containing TAF (tenofovir alafenamide fumarate).

The two healthcare groups said that the full results of this study will be presented at the 10th International AIDS Society Conference on HIV Science, which will be held in Mexico on 21 to 24 July.

Copyright (c) 2019 CercleFinance.com. All rights reserved.